

Zydus Nycomed commissions the newly expanded API manufacturing facility at Navi Mumbai

Mumbai, 29 September, 2010

- *The Joint Venture Company of Zydus Cadila and Nycomed, Zydus Nycomed, will become one of the largest API producers of the Active Pharmaceutical Ingredient (API) of Pantoprazole*
- *To emerge as a hub for global supplies of APIs to Nycomed for its branded generic portfolio*
- *Facility to manufacture complex, high-end APIs and will be audited by the European Medical Agency and other international regulatory authorities*

Zydus Nycomed, the joint venture company of Zydus Cadila and Nycomed, has commissioned its newly expanded API manufacturing facility at Navi Mumbai. The company is expected to start commercial production of APIs by December 2010. To start with, the plant will be manufacturing Pantoprazole, Urapidil and Lornoxicam. By 2011, the company will produce eight additional APIs.

The newly commissioned facilities mark the transition of Zydus Nycomed from an intermediate manufacturer to a full-fledged API manufacturer. Formed in 1998, the company is a 50:50 joint venture between Zydus Cadila and Nycomed.

The plant earlier provided high quality Key Starting Materials (KSMs) for manufacturing Pantoprazole. Besides other APIs, the expanded facility will now manufacture the active ingredient of Pantoprazole, Nycomed's key product for acid-related gastrointestinal diseases, making it one of the largest end-to-end manufacturers of this API in India.

Speaking on the occasion, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus Cadila, said: "This milestone marks a new beginning in the partnership that has been evolving and growing from strength to strength over the years. Zydus Nycomed has become a global hub of excellence with its high standards of quality, precision in manufacturing and customer service. The expansion of operations adds newer dimensions to this partnership and opens up new paths to excellence and growth."

Dr. Håkan Björklund, CEO, Nycomed emphasized: "Today's plant opening is a significant step forward to getting high quality APIs in Nycomed's branded generic portfolio produced at competitive costs. Having a time-tested and solid partnership in place, like we have with Zydus Cadila, gives me confidence we will continue to achieve our goal of getting medicines that matter to those who need them."

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. With an aim to be a research-based pharmaceutical company by 2020, Zydus Cadila has a team of over 370 research scientists working on new molecular entities at the state-of-the-art, Zydus Research Centre.

Globally, it has operations in US, Europe, Japan and Latin America, besides other emerging markets. Supporting its marketing prowess are the group's manufacturing facilities. The group has nine state-of-the-art, vertically integrated manufacturing facilities spread across five states in India of which, four are US FDA approved.

The group employs over 11,000 people worldwide and is dedicated to creating healthier lives globally. On a path of accelerated growth, the group posted a turnover of Rs. 3700 crore (\$ 800 mn) in 2009-10.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.